Just a few observations/comments on the Pedima package

New Post Public Reply Private Reply Replies (0) Message Board
thevibeguy weaver_525 #11598
581
Just a few observations/comments on the Pedima package insert:

Page 2 Intended Use:
Quote:
he GenViro!® COVID-19 Antigen test is only for use under the Food and Drug Administration’s Emergency Use Authorization.


This sounds to me like DECN may still be limited by our corrupt FDA. Maybe not great news.

Page 3 Principles of the Procedure
Quote:
A low-amplitude alternating voltage is then passed across the two electrodes and the resulting current is measured. As the virus concentration of the sample increases, the measured impedance increases, and quantitative detection according to the virus concentration is possible.


Earlier it said it was a qualitative test. Quantitative is better IMO. Might be a measure of confidence that the Covid19 bug is present?

Page 10 Positives and Negatives

Quote:
Number Tested Virus Result Result % [95% CI]
240 positive samples Sensitivity 87% [86.5% - 87.2%]
200 negative samples Specificity 98% [97.8% - 98.05%]
440 Total Positive Predictive Value 97% [96.9% - 97.2%]
Negative Predictive Value 90% [90.1% - 90.6%]
Total Accuracy 93%


Great numbers for a 10 second saliva test. It is difficult to find comparable numbers for the other lab or rapid tests, especially since they are testing for everything but the kitchen sink.

Page 10 Cross Sensitivities (Specificity)

Quote:
Cross Reactivity
GenViro!® COVID-19 Analytical Specificity Microorganisms
The following pathogens had no effect on the test result of the positives or the negatives, which were tested with GenViro! Covid-19 test. No cross reaction was observed. GenViro! Covid-19 test can differentiate between SARS-CoV und SARS-CoV-2.
Human coronavirus 229E concentration 1.5×104 TCID50/mL
Human coronavirus OC43 concentration 1.5×104 TCID50/mL
Human coronavirus NL63 concentration 1.5×104 TCID50/mL
Human coronavirus HKU1 concentration 1.5×104 TCID50/mL
MERS coronavirus concentration 1.5×104 TCID50/mL
SARS-CoV

11 - GENVIRO! SWIFT COVID-19 Product Insert Interference Substances reaction A dilution of SARS-Covid 2 (1.5×104 TCID50/mL) was added to the following substances at the stated concentrations. When tested with GenViro! Covid-19 test the substances showed no interference.

Influenza A H1N1 virus concentration 6×105 TCID50/mL
Influenza A H3N2 virus concentration 9×105 TCID50/mL
Influenza A H5N1 virus concentration 8×104 TCID50/mL
Influenza A H7N9 virus concentration 9×104 TCID50/mL
Influenza B concentration 3×105 TCID50/mL
Respiratory syncytial virus (RSV) type A/B concentration 3×105 TCID50/m


That is a VERY specific test. From what I can tell, those are much higher viral concentrations (4 to 6 times higher than the CV19) and they still don't affect the test. Again, since the powers that be want to keep this scamdemic going (IMO) a specific test will be impeded from entering the market (IMO). Notice how flu has disappeared this year? Yeah, hospitals are putting everything into the Covid bucket because they get paid so well to do that. Who can blame them? The WHO? Not likely.

All in all very positive information, IMO. I don't know how long the PTB will be able to keep a lid on this. Perhaps it will break out in other countries that are not as invested in Big Pharma making money preferring to help people instead?

I have a pie-in-the-sky dream that Berman is developing a NON-specific test that can identify a broad range of infections from the same sample in less than a minute. That would really be something, no? Probably a little busy at this point to dilute his resources and effort but a fella can dream...

Time will tell.

GLTA DECN shareholders.


Decision Diagnostics Corp (DECN) Stock Research Links

DECN Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

New CMO Joins ARTHEx: Boosting Innovative RNA Focus

Updated Category News Views 26

ARTHEx Biotech's Strategic Expansion Looks like ARTHEx Biotech is shaking things up with some strategic moves by bringing in Dr. Christian Freitag as their new Chief Medical Officer. Now, if you’re knee-deep in the biotech game, you'll know that having someone like Freitag onboard is akin to adding a star player to your lineup. The guy's got more than two decades of...

Continue Reading
Zinzino's October Sales Report: Eye on the Nutritional Prize

Updated Category News Views 38

Delving Into Zinzino's October Performance Alright, let’s cut to the chase and dive headfirst into what really matters—Zinzino AB’s preliminary sales report for October 2026. If you’re banking on the thriving nutritional supplement sector, this Swedish company’s numbers might just be your radar’s blip. October wasn’t just any month for these folks; it was a...

Continue Reading
Are BWIN, LFCR, PCRX Shareholder Deals Fair?

Updated Category News Views 113

What's Really Going On with BWIN, LFCR, and PCRX? Everyone talks about when there's smoke, there's fire. But in this case, it’s hard not to wonder if we're standing knee-deep in burning embers, or just a dusty old campfire. Halper Sadeh LLC is ringing the alarm bells for Baldwin Group, Lifecore Biomedical, and Pacira BioSciences, the trio tagged under NASDAQ: BWIN,...

Continue Reading
Starting Pet End-of-Life Talks: Why Timing Matters

Updated Category News Views 23

Early Conversations Can Change Everything The minute you bring it up, let's be honest, nobody likes to talk about end-of-life decisions, not even for their pets. Yet, when you think about it, biding your time until things get critical isn't doing anyone any favors, especially not the furry ones. Drs. Brandon and Paola Beebout, two piercing minds from Kearney, Nebraska,...

Continue Reading
Kendra Scott's 'Long Live Joy' Campaign Dazzles

Updated Category News Views 40

Unveiling a Holiday Spectacle: 'Long Live Joy' Party hats off, folks, because Kendra Scott is stepping up the holiday game with something they’re calling 'Long Live Joy'. Now, we're not just talking about any run-of-the-mill marketing fluff. This one’s big, it’s colorful, and it’s here to make your accessorized holidays a tad more enchanting. The Multi-Faceted...

Continue Reading
RideNow Gears Up for Earnings Amidst Industry Shifts

Updated Category News Views 185

Highway to Earnings: RideNow's Third Quarter Call Alright, folks, this is the moment the powersports crowd has been itching for. RideNow Group, Inc. (NASDAQ: RDNW) is set to roll out their third-quarter financial results on November 10, 2026. If you're in for a wild ride—pun fully intended—mark this on your calendars. With this company hogging the spotlight in the...

Continue Reading
Duolingo Faces Class Action: Investors React Strongly

Updated Category News Views 63

Duolingo's Rough Road: A Lawsuit in Motion Alright, fasten your seatbelts, because we've got a real rollercoaster here with Duolingo (NASDAQ: DUOL). You know, the language-learning app that's been pushing ads like it's going out of style? Well, investors are seeing red—not the kind you want, either. This class action lawsuit looming over them is like an unwelcome...

Continue Reading
Crocs™ Gains C2C Circularity Gold for Classic Clogs

Updated Category News Views 81

Turning Plastic into Gold Well, folks, Crocs isn't just about comfort anymore. They're wrapping their iconic Classic Clog in a shiny new accolade: Cradle to Cradle Certified® Circularity Gold Version 5.0. Imagine that—an award for making something meant to last, designed to be repurposed. They're not just slapping new paint on the same old clogs either. This...

Continue Reading
Baidu Faces Fraud Allegations: What Investors Should Know

Updated Category News Views 196

Trouble on the Horizon for Baidu Shareholders If you've got a pulse in the world of stock trading, you've likely caught wind of the storm brewing over at Baidu, Inc. (NASDAQ: BIDU). We're talking some heavy-duty allegations of securities fraud, and a class action lawsuit that's got investors scrutinizing their portfolios like never before. The lawsuit's been filed in the...

Continue Reading
AllianceBernstein Unveils Income-Focused ETF Amid Volatile Times

Updated Category News Views 40

Diving into AllianceBernstein's New Income ETF Well, today we’ve got something stirring in the financial waters over at AllianceBernstein. They’ve launched a new exchange-traded fund (ETF), aptly named the AB Equity Premium Income ETF [INK]. Now, if you’re wondering what’s cooking with this newcomer on the NASDAQ, let’s crack it open and see what’s under the...

Continue Reading

Top 5 Most Recently Viewed Articles

Keyo Elevates Rudy Dajie to CEO, Driving Innovative Payments

Updated Category News Views 237

Keyo Appoints Rudy Dajie as New CEO for Advanced Payment Solutions Keyo has recently announced a game-changing leadership appointment with Rudy Dajie stepping into the role of Chief Executive Officer. In a world where artificial intelligence is rapidly evolving, the demand for enhanced security in biometric identification is greater than ever. Innovative Biometric...

Continue Reading
Final Call for $XPL Token Access: Join the XploraDEX Journey

Updated Category News Views 162

Final Chance to Participate in $XPL Token Distribution The $XPL token distribution is entering its crucial final phase, marking an exciting moment for both investors and traders. As the presale of XploraDEX nears its closing date, many are eager to grab their share of the tokens before the opportunity slips away. This innovative platform, set on the XRP Ledger, has the...

Continue Reading
Promising Small-Cap Stocks on the Rise for Investors

Updated Category News Views 73

Small-Cap Stocks on the Verge of Growth As 2024 progresses, many analysts have identified a resurgence in small-cap stocks, suggesting that this year could mark a turning point for these often-overlooked companies. With the economic landscape shifting, especially as interest rates stabilize, there is renewed hope for sectors that faced challenges in previous years....

Continue Reading
Eli Lilly's New Oral Diabetes Treatment Python Results Exceed Expectations

Updated Category News Views 204

Eli Lilly's Groundbreaking Diabetes Treatment Trials Eli Lilly and Company (NYSE: LLY) has made significant advancements in the treatment of type 2 diabetes with their oral medication, orforglipron. Recent Phase 3 trials, ACHIEVE-2 and ACHIEVE-5, have demonstrated impressive results in controlling blood sugar levels among participants. ACHIEVE Trials Overview The...

Continue Reading
Experience Luxury and Performance with the 2025 LC 500 Convertible

Updated Category News Views 63

Introducing the 2025 LC 500 Convertible The 2025 LC 500 Convertible marks another exciting development in the luxury automobile market, maintaining its prestige and allure. This model has undergone a few updates and is ready to impress enthusiasts and casual drivers alike. Standout Features of the 2025 Model This year's model comes with notable enhancements, including...

Continue Reading